In particular, the positive outcomes from animal studies have led to multiple clinical trials examining the potential of combining IDO1 inhibitor in combination treatments for cancer patients, including six clinical trials with BrCa patients. The gene discussed is IDO1; the disease is invasive breast carcinoma.